Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation James A.

Slides:

Advertisements

Similar presentations

Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia Michael R. Verneris, Mary Eapen,

Advertisements

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies Marcelo C. Pasquini,

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation Norihiro.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function Cameron.

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience

Allogeneic Stem Cell Transplantation in Myelofibrosis

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis Danielle H. Oh, Haocheng.

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Navneet S. Majhail, Elizabeth A. Murphy, Nancy A

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Betty T. Tran, Abigail Halperin, Jason W. Chien

The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces.

Jörg D. Seebach, Georg Stussi, Jakob R. Passweg, Fausto R

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Biology of Blood and Marrow Transplantation

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Pharmacokinetics of Mycophenolic Acid Administered 3 Times Daily after Hematopoietic Stem Cell Transplantation with Reduced-Intensity Regimen Bernard.

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

Immune Cell Subset Counts Associated with Graft-versus-Host Disease

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.

The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients Marilyn J. Hammer, Corey Casper, Ted A. Gooley,

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children.

Transplantation from Matched Siblings Using Once-Daily Intravenous Busulfan/Fludarabine with Thymoglobulin: A Myeloablative Regimen with Low Nonrelapse.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell.

Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine- Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Blood and Marrow Transplant Handbook

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

by Rosy Dabas, Kareem Jamani, Shahbal B

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation Janelle.

Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation Francis Ayuk, Galina.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study Moshe Yeshurun,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Once Daily i. v. Busulfan and Fludarabine (i. v

Presentation transcript:

Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation James A. Russell, Shahbal B. Kangarloo, Tyler Williamson, M. Ahsan Chaudhry, Mary Lynn Savoie, A. Robert Turner, Loree Larratt, Jan Storek, Nizar J. Bahlis, Mona Shafey, Christopher B. Brown, Maggie Yang, Michelle Geddes, Nancy Zacarias, Ping Yue, Peter Duggan, Douglas A. Stewart, Andrew Daly Biology of Blood and Marrow Transplantation Volume 19, Issue 9, Pages 1381-1386 (September 2013) DOI: 10.1016/j.bbmt.2013.07.002 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier plots of grade II-IV aGVHD (A) and grade III-IV aGVHD (B). Groups 1 and 2 (solid line) had a Bu AUC below the median, whereas groups 3 and 4 (dotted line) had a Bu AUC above the median. Biology of Blood and Marrow Transplantation 2013 19, 1381-1386DOI: (10.1016/j.bbmt.2013.07.002) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier plots of OS (A), DFS (B), and NRM (C). Groups 1 and 4 (dotted line) had a Bu AUC outside the range of 3814 to 4993 μM/min, whereas groups 2 and 3 (solid line) had a Bu AUC within that range. Biology of Blood and Marrow Transplantation 2013 19, 1381-1386DOI: (10.1016/j.bbmt.2013.07.002) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Kaplan-Meier plots of relapse. Biology of Blood and Marrow Transplantation 2013 19, 1381-1386DOI: (10.1016/j.bbmt.2013.07.002) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions